- Serlopitant, a neurokinin 1 receptor antagonist, is associated with improved itch symptoms in patients with psoriatic pruritus, according to a phase 2 clinical trial.
Why this matters
- Many available treatment options for psoriasis do not adequately address pruritus.
- Vs placebo, serlopitant was associated with a higher worst itch numeric rating scale (WI-NRS) response rate at:
- 4 weeks: 20.8% vs 11.5% (P=.039).
- 8 weeks: 33.3% vs 21.1% (P=.028).
- 4.9% of patients who received serlopitant and 4.0% of patients who received placebo experienced treatment-related adverse events.
- 204 patients with psoriatic pruritus were randomly assigned to serlopitant 5 mg or placebo daily for 8 weeks.
- Funding: Menlo Therapeutics, Inc.
- Relatively small patient sample size.
- Short trial duration.
- Patients with severe psoriasis were excluded.